MA32385B1 - Forme posologique pharmaceutique en capsule comprenant une formulation en suspension d'un derive d'indolinone - Google Patents

Forme posologique pharmaceutique en capsule comprenant une formulation en suspension d'un derive d'indolinone

Info

Publication number
MA32385B1
MA32385B1 MA33402A MA33402A MA32385B1 MA 32385 B1 MA32385 B1 MA 32385B1 MA 33402 A MA33402 A MA 33402A MA 33402 A MA33402 A MA 33402A MA 32385 B1 MA32385 B1 MA 32385B1
Authority
MA
Morocco
Prior art keywords
capsule
dosage form
pharmaceutical dosage
suspension formulation
indolinone derivative
Prior art date
Application number
MA33402A
Other languages
Arabic (ar)
English (en)
Inventor
Thomas Bock
Werner Brox
Roman Messerschmid
Rudolf Binder
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40911908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32385(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA32385B1 publication Critical patent/MA32385B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une formulation en suspension dont le principe actif est le 3-z-[1-(4- (n-((4-méthyl-pipérazin-1-yl)-méthylcarbonyl)-n-méthyl-amino)-anilino)-1-phényl-méthylène]-6- méthoxycarbonyl-2- indolinone-monoéthane-sulphonate. L'invention concerne également, d'une part une forme posologique pharmaceutique en capsule contenant ladite formulation en suspension, d'autre part un procédé d'élaboration de ladite formulation en suspension, mais aussi un procédé d'élaboration de ladite capsule comprenant ladite formulation en suspension, et également le matériau d'enveloppe de la capsule.
MA33402A 2008-06-06 2010-12-06 Forme posologique pharmaceutique en capsule comprenant une formulation en suspension d'un derive d'indolinone MA32385B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08157748 2008-06-06
PCT/EP2009/056878 WO2009147212A1 (fr) 2008-06-06 2009-06-04 Forme posologique pharmaceutique en capsule comprenant une formulation en suspension d'un dérivé d'indolinone

Publications (1)

Publication Number Publication Date
MA32385B1 true MA32385B1 (fr) 2011-06-01

Family

ID=40911908

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33402A MA32385B1 (fr) 2008-06-06 2010-12-06 Forme posologique pharmaceutique en capsule comprenant une formulation en suspension d'un derive d'indolinone

Country Status (35)

Country Link
US (4) US20110301177A1 (fr)
EP (1) EP2299987B1 (fr)
JP (2) JP5661031B2 (fr)
KR (2) KR20170020557A (fr)
CN (2) CN102056598B (fr)
AR (1) AR072059A1 (fr)
AU (1) AU2009254548B2 (fr)
BR (1) BRPI0913434B8 (fr)
CA (1) CA2726267C (fr)
CL (1) CL2010001279A1 (fr)
CO (1) CO6280467A2 (fr)
CY (1) CY1120533T1 (fr)
DK (1) DK2299987T3 (fr)
EA (1) EA029996B1 (fr)
EC (1) ECSP10010660A (fr)
ES (1) ES2669469T3 (fr)
HR (1) HRP20180709T1 (fr)
HU (1) HUE039187T2 (fr)
IL (1) IL208954A (fr)
LT (1) LT2299987T (fr)
MA (1) MA32385B1 (fr)
MX (2) MX359229B (fr)
MY (1) MY158930A (fr)
NO (1) NO2299987T3 (fr)
NZ (1) NZ603162A (fr)
PE (1) PE20100254A1 (fr)
PL (1) PL2299987T3 (fr)
PT (1) PT2299987T (fr)
RS (1) RS57142B1 (fr)
SI (1) SI2299987T1 (fr)
TW (1) TW201002691A (fr)
UA (1) UA104590C2 (fr)
UY (1) UY31879A (fr)
WO (1) WO2009147212A1 (fr)
ZA (1) ZA201007636B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
UA104590C2 (ru) 2008-06-06 2014-02-25 Берингер Ингельхайм Интернациональ Гмбх Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона
JO3587B1 (ar) 2010-06-02 2020-07-05 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
JP2015532272A (ja) 2012-09-28 2015-11-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
EP3782604A1 (fr) 2013-07-31 2021-02-24 Windward Pharma, Inc. Composés inhibiteurs de tyrosine kinase en aérosol et leurs utilisations
US20150209360A1 (en) * 2014-01-30 2015-07-30 Orbz, Llc Oral caffeine delivery composition
CN114504562A (zh) * 2015-03-13 2022-05-17 江苏豪森药业集团有限公司 含有吲哚满酮衍生物混悬液的胶囊制剂及其制备方法
KR20260025887A (ko) 2015-06-06 2026-02-24 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
CN107019697A (zh) * 2016-02-02 2017-08-08 瑞阳(苏州)生物科技有限公司 预防或治疗纤维化疾病的药物组合物及其应用
AU2017274195B2 (en) 2016-06-02 2022-04-07 Ads Therapeutics Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
US10561630B2 (en) * 2016-10-25 2020-02-18 Glykon Technologies Group, Llc Hydroxycitric acid compounds and capsule liquid delivery
CN108066343A (zh) * 2016-11-08 2018-05-25 瑞阳(苏州)生物科技有限公司 一种预防或治疗肾纤维化疾病的药物
JP2019536812A (ja) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
CN110573161A (zh) 2017-03-28 2019-12-13 勃林格殷格翰国际有限公司 用于治疗肌营养不良的方法的尼达尼布
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
IL273169B2 (en) 2017-10-23 2024-05-01 Boehringer Ingelheim Int New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
WO2019106692A1 (fr) * 2017-11-29 2019-06-06 Sun Pharmaceutical Industries Limited Suspension orale de nintedanib esylate
FI3761980T3 (fi) 2018-03-07 2024-02-21 Pliant Therapeutics Inc Aminohappoyhdisteitä ja käyttömenetelmiä
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
WO2020053665A2 (fr) * 2018-09-13 2020-03-19 Ftf Pharma Private Limited Suspensions pharmaceutiques chimiothérapeutiques de dosage perorale
WO2020079706A1 (fr) * 2018-10-15 2020-04-23 Cipla Limited Formulation pharmaceutique
CN112386580B (zh) * 2019-08-13 2022-07-08 齐鲁制药有限公司 具有改善的溶出度和稳定性的尼达尼布药物制剂、制备方法及其应用
JP7665619B2 (ja) 2019-12-04 2025-04-21 イドルシア・ファーマシューティカルズ・リミテッド 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤
US20230135671A1 (en) 2020-04-01 2023-05-04 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions
EP4098246A1 (fr) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation de nintedanib
TW202329973A (zh) * 2021-10-14 2023-08-01 美商普萊恩醫療公司 整合素抑制劑及其與其他藥劑併用之用途
CN114404382B (zh) * 2022-01-24 2023-05-12 南京康川济医药科技有限公司 乙磺酸尼达尼布软胶囊及其制备方法
US20250161250A1 (en) 2022-02-28 2025-05-22 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis
CN119630398A (zh) 2022-08-16 2025-03-14 勃林格殷格翰国际有限公司 眼内用尼达尼布的药物制剂
AU2025200733A1 (en) * 2024-02-05 2025-08-21 Anxo Pharmaceutical Co., Ltd. Pharmaceutical composition and method using the same
WO2025254255A1 (fr) 2024-06-05 2025-12-11 영진약품 주식회사 Nouveau comprimé ayant une vitesse de dissolution améliorée comprenant du nintedanib ou un sel pharmaceutiquement acceptable de celui-ci et son procédé de préparation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870062A (en) 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
GB8305693D0 (en) 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
DE3579384D1 (de) 1984-07-24 1990-10-04 Scherer Gmbh R P Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung.
GB9313329D0 (en) * 1993-06-28 1993-08-11 Scherer Ltd R P Softgel capsule shell compositions
DE19603402A1 (de) 1995-02-24 1996-08-29 Basf Ag Weichgelatinekapseln
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
JP2004531537A (ja) * 2001-05-01 2004-10-14 ファイザー・プロダクツ・インク 一様な薬剤分布と効力を有する低用量製薬組成物の製造方法
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20060293260A1 (en) * 2005-05-24 2006-12-28 Wyeth Useful high load concentrate compositions for control of ecto-and endo-parasites
PT1948180E (pt) * 2005-11-11 2013-05-10 Boehringer Ingelheim Int Tratamento de combinação de cancro compreendendo inibidores de egfr/her2
UA104590C2 (ru) 2008-06-06 2014-02-25 Берингер Ингельхайм Интернациональ Гмбх Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
ME02273B (me) * 2008-06-06 2016-02-20 Boehringer Ingelheim Int Farmaceutska kombinacija
US20120157472A1 (en) 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
US20120142703A1 (en) 2009-05-14 2012-06-07 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases

Also Published As

Publication number Publication date
WO2009147212A1 (fr) 2009-12-10
CA2726267A1 (fr) 2009-12-10
NO2299987T3 (fr) 2018-07-21
CA2726267C (fr) 2017-10-31
CN102056598B (zh) 2017-09-19
AU2009254548A1 (en) 2009-12-10
JP2011522812A (ja) 2011-08-04
MX2010013203A (es) 2011-02-25
KR20170020557A (ko) 2017-02-22
AR072059A1 (es) 2010-08-04
EP2299987B1 (fr) 2018-02-21
PL2299987T3 (pl) 2018-08-31
BRPI0913434B1 (pt) 2020-10-13
CO6280467A2 (es) 2011-05-20
EA201001856A1 (ru) 2011-06-30
LT2299987T (lt) 2018-05-25
SI2299987T1 (en) 2018-06-29
US20140004187A1 (en) 2014-01-02
ES2669469T3 (es) 2018-05-25
US20160022672A1 (en) 2016-01-28
CY1120533T1 (el) 2019-07-10
ECSP10010660A (es) 2011-02-28
CN102056598A (zh) 2011-05-11
PT2299987T (pt) 2018-05-21
JP5905542B2 (ja) 2016-04-20
TW201002691A (en) 2010-01-16
EA029996B1 (ru) 2018-06-29
DK2299987T3 (en) 2018-05-22
UY31879A (es) 2010-01-29
HUE039187T2 (hu) 2018-12-28
PE20100254A1 (es) 2010-04-21
AU2009254548B2 (en) 2015-10-01
BRPI0913434A2 (pt) 2015-12-01
CL2010001279A1 (es) 2011-05-13
US9907756B2 (en) 2018-03-06
US20110301177A1 (en) 2011-12-08
JP2014208712A (ja) 2014-11-06
IL208954A (en) 2017-11-30
IL208954A0 (en) 2011-01-31
KR101725469B1 (ko) 2017-04-11
EP2299987A1 (fr) 2011-03-30
JP5661031B2 (ja) 2015-01-28
KR20110017872A (ko) 2011-02-22
NZ603162A (en) 2014-05-30
RS57142B1 (sr) 2018-07-31
MY158930A (en) 2016-11-30
CN105193720A (zh) 2015-12-30
BRPI0913434B8 (pt) 2021-05-25
MX359229B (es) 2018-09-20
CN105193720B (zh) 2018-07-31
UA104590C2 (ru) 2014-02-25
US20160324791A1 (en) 2016-11-10
ZA201007636B (en) 2011-08-31
HRP20180709T1 (hr) 2018-06-15

Similar Documents

Publication Publication Date Title
MA32385B1 (fr) Forme posologique pharmaceutique en capsule comprenant une formulation en suspension d'un derive d'indolinone
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
MX2014013696A (es) Derivado de pirazol y uso del mismo para propositos medicos.
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
EA201290654A1 (ru) Новые замещенные триазольные производные как модуляторы гамма-секретазы
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
EA201171363A1 (ru) Новые замещенные производные индазола и азаиндазола в качестве модуляторов гамма-секретазы
MA39088B1 (fr) Compositions et procédés pour moduler des récepteurs farnesoïde x
CU23914B1 (es) DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL CoA
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
IN2014MN00258A (fr)
EA201170829A1 (ru) Замещенные бициклические производные имидазола в качестве модуляторов гамма-секретазы
MA32386B1 (fr) Forme posologique pharmaceutique pour libération immédiate de dérivé d'indolinone
MA37610B1 (fr) Formulations de testostérone proliposomales
MX394108B (es) Derivados de indol n-sustituidos.
MX389600B (es) Nueva composición terapéutica que contiene ingrediente activo de apomorfinas.
MA38854B1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
CR20110704A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amilodipina, su preparación y su aplicación terapéutica
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
AR073265A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
RU2009131745A (ru) Лекарственное средство для профилактического и/или терапевтического лечения деменции по типу альцгеймера
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu